SCHEDULE 13D
This Amendment No. 1 (Amendment No. 1) amends and supplements the Schedule 13D (the Initial Schedule 13D and
together with this Amendment No. 1, the Schedule 13D) filed with the Securities and Exchange Commission on June 1, 2022 by CBI USA, Inc. (the Reporting Person) with respect to the Common Stock, par value $0.0001 per
share, of Exicure, Inc. (Exicure or the Company). Capitalized terms used herein and not otherwise defined in this Amendment No. 1 shall have the meanings set forth in the Initial Schedule 13D. This Amendment No. 1
amends Items 2, 3, 4, 5, 6 and 7 to the extent set forth below.
Item 2. Identity and Background
Item 2 is amended and restated in its entirety to read as follows:
This Schedule 13D is being filed by CBI USA, Inc., a Delaware corporation (the Reporting Person). The address of the Reporting
Person is 3000 Western Avenue, Suite 400, Seattle, WA 98121. The principal business of the Reporting Person to invest in dynamic businesses initially in the life sciences.
The Reporting Person is a subsidiary of CBI Co. Ltd., a Korea-based and listed company (CBI Co). The address of CBI Co is 208,
namdong-daero, namdong-gu, Incheon, Republic of Korea (21643). The principal business of the CBI Co is a manufacturer of automotive engine and mission parts.
The name, business address, principal occupation and citizenship of (1) each executive officer and direct of the Reporting Person and
(2) each executive officer and director of CBI Co is set forth on Schedule 1 hereto.
(d) During the last five years, neither
the Reporting Person nor other person identified in this Item 2 has been convicted in a criminal proceeding.
(e) During the last five
years, neither the Reporting Person nor other person identified in this Item 2 was a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment,
decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws, or finding any violation with respect to such laws.
Item 3. Source and Amount of Funds
Item 3 is supplemented as follows:
With respect to the purchase pursuant to the Securities Purchase Agreement dated September 26, 2022 as described in Item 5 below, the
Reporting Person expects to use its available working capital together with funds from CBI Co to fund the acquisition of 3,400,000 shares of Common Stock at a price per share of $1.60 for an aggregate purchase price of $5,440,000.
2